Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Tony Mok, Yi‐Long Wu, Iveta Kudaba, +249

The Lancet

Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab

Kimio Yonesaka, Kreshnik Zejnullahu, Isamu Okamoto, +29

Science Translational Medicine

Cetuximab SensitivityOncologyErbb2 SignalingSignaling PathwayMedicine +13

Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): a multicentre, phase 2 trial

Jun Sato, Miyako Satouchi, Shoichi Itoh, +14

The Lancet Oncology

OncologyMetastatic Thymic CarcinomaMetronomic TherapyPathologyCancer Treatment +3

A Phase I Dose-Escalation Study of ZD6474 in Japanese Patients with Solid, Malignant Tumors

Tomohide Tamura, Hironobu Minami, Yasuhide Yamada, +12

Journal of Thoracic Oncology

Dose-escalation StudyMedicineMalignant TumorsCancer TreatmentClinical Radiation Oncology +6

Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumors

Noboru Yamamoto, Atsushi Horiike, Yasuhito Fujisaka, +4

Cancer Chemotherapy and Pharmacology

OncologySolid TumorsMedicinePharmacokinetic StudyCancer Growth +5

A Phase I Dose-Escalation Study of ZD6474 in Japanese Patients with Solid, Malignant Tumors

Tomohide Tamura, Hironobu Minami, Yasuhide Yamada, +12

Journal of Thoracic Oncology

Dose-escalation StudyMedicineMalignant TumorsCancer TreatmentClinical Radiation Oncology +6

Switching addictions between HER2 and FGFR2 in HER2-positive breast tumor cells: FGFR2 as a potential target for salvage after lapatinib failure

Koichi Azuma, Junji Tsurutani, Kazuko Sakai, +10

Biochemical and Biophysical Research Communications

Breast OncologyLapatinib FailureMedicinePharmacologyCancer Biology +7

Phase I study of amatuximab, a novel monoclonal antibody to mesothelin, in Japanese patients with advanced solid tumors

Yasuhito Fujisaka, Takayasu Kurata, Kaoru Tanaka, +8

Investigational New Drugs

Randomised, phase III trial of epoetin-β to treat chemotherapy-induced anaemia according to the EU regulation

Yasuhito Fujisaka, Toru Sugiyama, Hiroshi Saito, +6

British Journal of Cancer

Pilot study of duloxetine for cancer patients with neuropathic pain non-responsive to pregabalin.

Hiromichi Matsuoka, Chihiro Makimura, Atsuko Koyama, +6

PubMed